In breast cancer, the BRD4 inhibitor JQ1 and the KAT5 inhibitor ketamine promote ferroptosis by epigenetic regulation of SIRT1/G9a and GPX4 respectively, and the former is also effective in LUAD.69, 72. Here, KAT5 is linked to breast carcinoma.